Inhaltsverzeichnis
Anzeigen
Making Pharmacoeconomics In Formulary Development a Reality
Despite what might be commonly believed, pharmacoeconomics is not a widely used tool for formulary development. Here’s a model to follow.
T. Jeffrey White, Pharm.D., M.S.
When it comes to information-sharing, just when does ‘no’ mean ‘no’? What about conflicting statutes? We have two years to sort it out.
Michael Levin-Epstein
There’s a difference between plausibility and wishful thinking that many who predict the advent of this system fail to recognize. Risk adjusting, adverse selection, and the tax code present hurdles.
Frank Diamond
While health plans have embraced alternative therapies, there’s little agreement on how to bill for them. The ability to demonstrate outcomes may help.
Debra Gordon
Unintentional bias can be just as damaging as the overt brand, according to the president of the National Medical Association.
Patrick Mullen
Christopher M. Dezii, R.N., M.B.A.
Departments
WASHINGTON WATCH
Michael Levin-Epstein
COMPENSATION MONITOR
SYSTEMS & SOFTWARE
Joyce R. Ochs
ETHICS
Michael S. Victoroff, M.D.
MANAGED CARE OUTLOOK
News & Commentary
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.